Agendia announced Laura van 't Veer would receive the PMWC Luminary Award for co-inventing MammaPrint and advancing precision oncology.
On January 17, 2020, Agendia publicly announced that Laura van 't Veer would be honored with the Precision Medicine World Conference (PMWC) Luminary Award, to be presented later that month at the conference in Silicon Valley.
The announcement recognized van 't Veer's foundational role in co-inventing MammaPrint, the 70-gene expression assay that helped launch the field of genomic risk stratification for breast cancer patients. The PMWC Luminary Award is reserved for individuals whose work has had a transformative and lasting impact on the practice of precision medicine.
This announcement served to build anticipation within the scientific and medical community for the formal award ceremony, and it highlighted van 't Veer's sustained influence nearly two decades after her original 2001 discovery of the 70-gene signature. It also reflected the growing recognition of molecular diagnostics as central to modern oncology practice, an area in which van 't Veer had been an early pioneer.
The announcement further solidified her standing among the most celebrated translational researchers in breast cancer care, someone whose bench-to-bedside work had reshaped clinical guidelines internationally.